[go: up one dir, main page]

PT3031907T - Materiais e métodos para melhorar procedimentos de enxerto de células estaminais hematopoiéticas - Google Patents

Materiais e métodos para melhorar procedimentos de enxerto de células estaminais hematopoiéticas

Info

Publication number
PT3031907T
PT3031907T PT161535265T PT16153526T PT3031907T PT 3031907 T PT3031907 T PT 3031907T PT 161535265 T PT161535265 T PT 161535265T PT 16153526 T PT16153526 T PT 16153526T PT 3031907 T PT3031907 T PT 3031907T
Authority
PT
Portugal
Prior art keywords
materials
methods
stem cells
hematopoietic stem
enhance hematopoietic
Prior art date
Application number
PT161535265T
Other languages
English (en)
Original Assignee
Univ Indiana Res & Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42153284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3031907(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Indiana Res & Tech Corp filed Critical Univ Indiana Res & Tech Corp
Publication of PT3031907T publication Critical patent/PT3031907T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/99—Miscellaneous (1.14.99)
    • C12Y114/99001—Prostaglandin-endoperoxide synthase (1.14.99.1), i.e. cyclooxygenase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pregnancy & Childbirth (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
PT161535265T 2008-11-06 2009-11-06 Materiais e métodos para melhorar procedimentos de enxerto de células estaminais hematopoiéticas PT3031907T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11201808P 2008-11-06 2008-11-06

Publications (1)

Publication Number Publication Date
PT3031907T true PT3031907T (pt) 2021-01-28

Family

ID=42153284

Family Applications (1)

Application Number Title Priority Date Filing Date
PT161535265T PT3031907T (pt) 2008-11-06 2009-11-06 Materiais e métodos para melhorar procedimentos de enxerto de células estaminais hematopoiéticas

Country Status (10)

Country Link
US (5) US9107909B2 (pt)
EP (3) EP2362733B1 (pt)
JP (5) JP5846915B2 (pt)
CN (4) CN107630001A (pt)
AU (4) AU2009313290B2 (pt)
CA (3) CA2742876C (pt)
ES (1) ES2845641T3 (pt)
PT (1) PT3031907T (pt)
WO (1) WO2010054271A1 (pt)
ZA (1) ZA201804932B (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006304392B2 (en) 2005-10-18 2014-05-01 National Jewish Health Conditionally immortalized long-term stem cells and methods of making and using such cells
SG10201803982TA (en) 2008-05-16 2018-07-30 Taiga Biotechnologies Inc Antibodies and processes for preparing the same
EP2966084B1 (en) 2008-08-28 2018-04-25 Taiga Biotechnologies, Inc. Modulators of myc, methods of using the same and methods of identifying agents that modulate myc
CA2742876C (en) 2008-11-06 2018-08-21 Indiana University Research & Technology Corporation Materials and methods to enhance hematopoietic stem cells engraftment procedures
US10813917B2 (en) 2009-12-11 2020-10-27 Medregen, Llc Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
CA2807944C (en) * 2010-08-12 2020-02-18 Fate Therapeutics, Inc. Improved hematopoietic stem and progenitor cell therapy
AU2012206517B2 (en) 2011-01-13 2016-12-01 Scipharm Sarl Method for Enhancing Engraftment of Haematopoietic Stem Cells
DK2760994T4 (da) 2011-09-30 2021-10-11 Bluebird Bio Inc Forbindelser til forøget viral transduktion
WO2013082241A2 (en) 2011-12-02 2013-06-06 Fate Therapeutics, Inc. Improved methods of treating ischemia
CA2857640C (en) * 2011-12-02 2021-11-16 Fate Therapeutics, Inc. Enhanced stem cell composition
US9233127B2 (en) 2012-02-29 2016-01-12 University Of Virginia Patent Foundation Compositions and methods for CXCR4 signaling and umbilical cord blood stem cell engraftment
WO2014015318A1 (en) * 2012-07-19 2014-01-23 Bluebird Bio, Inc. Soluble compounds for improved gene therapy methods
CN110643576A (zh) * 2012-07-20 2020-01-03 泰加生物工艺学公司 造血区室的增强的重建和自动重建
WO2014026110A2 (en) * 2012-08-10 2014-02-13 Bluebird Bio, Inc. Compounds for improved viral transduction
CN113616779A (zh) 2013-02-28 2021-11-09 哈佛学院校长同事会 用于动员干细胞的方法和组合物
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
EP2968416A4 (en) 2013-03-15 2016-08-17 Fate Therapeutics Inc CELL POTENTIAL TEST FOR THERAPEUTIC POTENTIAL
US9943545B2 (en) 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
WO2014179266A2 (en) 2013-04-29 2014-11-06 The Johns Hopkins University Wound healing via autologous stem cell mobilization
KR101489861B1 (ko) * 2013-05-07 2015-02-05 경북대학교 산학협력단 Amd3100을 포함하는 골질환 예방 또는 치료용 조성물
WO2016123117A1 (en) 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Cells with increased immuno-regulatory properties and methods for their use and manufacture
CN104774806B (zh) * 2015-04-09 2019-02-15 广州赛莱拉干细胞科技股份有限公司 一种胎盘造血干细胞的制备方法
AU2016296741A1 (en) 2015-07-21 2018-02-22 The Children's Medical Center Corporation PD-L1 expressing hematopoietic stem cells and uses
EP4151720B1 (en) 2016-02-12 2024-08-07 bluebird bio, Inc. Vcn enhancer compositions and methods of using the same
EP3413896B1 (en) 2016-02-12 2021-03-17 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same
JP2019507596A (ja) * 2016-02-26 2019-03-22 プレジデント アンド フェローズ オブ ハーバード カレッジ 生着性の高い造血幹細胞
WO2018017341A1 (en) * 2016-07-22 2018-01-25 Senlin Li Methods and compositions for rejuvenation
US10583156B2 (en) 2016-12-02 2020-03-10 Taiga Biotechnologies, Inc. Nanoparticle formulations
JP7175277B2 (ja) * 2017-01-27 2022-11-18 チルドレンズ ホスピタル メディカル センター 造血幹細胞の生着活性を向上させる方法
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
US11213546B2 (en) 2017-09-07 2022-01-04 Emory University Methods to mobilize tissue resident cells for adoptive t cell therapy
WO2019060708A1 (en) 2017-09-22 2019-03-28 The Children's Medical Center Corporation TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS
FR3074189A1 (fr) * 2017-11-30 2019-05-31 Assistance Publique - Hopitaux De Paris Methode de generation de greffons de cellules souches hematopoietiques
CN108404112B (zh) * 2018-04-01 2020-05-12 北京诺赛启研再生医学研究院有限公司 提高造血干细胞归巢及植入率的方法及其试剂
EP3647413A1 (en) * 2018-10-31 2020-05-06 Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas O.A., M.P. (CIEMAT) Improvements for performing and facilitating the recovery after hematopoietic stem cell transplantation
CN113874033A (zh) 2019-04-08 2021-12-31 泰加生物工艺学公司 用于冷冻保存免疫细胞的组合物和方法
JP2022532608A (ja) 2019-05-14 2022-07-15 タイガ バイオテクノロジーズ，インク． Ｔ細胞疲弊を処置するための組成物および方法
KR20220160018A (ko) 2020-03-31 2022-12-05 덴카 주식회사 알루미나 분말, 수지 조성물, 및 방열 부품
CN116509834B (zh) * 2023-01-20 2025-05-13 东北师范大学 化合物在制备造血干/祖细胞增殖和损伤修复药物中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399493A (en) 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
JPH08205860A (ja) * 1994-01-21 1996-08-13 Usa Government 造血細胞の膨大化および移植方法
US5928638A (en) * 1996-06-17 1999-07-27 Systemix, Inc. Methods for gene transfer
NZ532060A (en) * 2001-10-02 2005-11-25 Inst Clayton De La Rech Methods and compositions relating to restricted expression lentiviral vectors and their applications
WO2003047635A1 (en) * 2001-12-06 2003-06-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of cd34+ hematopoietic progenitor cells for the treatment of cns disorders
EP1471818A4 (en) * 2002-02-04 2007-03-28 Millennium Pharm Inc METHOD AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISEASES USING 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137 , 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 OR 13249 MOLECULES
CA2519975C (en) 2003-04-08 2013-07-02 Yeda Research And Development Co. Ltd Stem cells having increased sensitivity to a chemoattractant and methods of generating and using same
IL158868A0 (en) 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
EP1760071A4 (en) * 2004-06-23 2008-03-05 Ono Pharmaceutical Co COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF
US20080021078A1 (en) 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
WO2007041511A2 (en) * 2005-09-30 2007-04-12 New York University Hematopoietic progenitor kinase 1 for modulation of an immune response
JP2007099724A (ja) 2005-10-06 2007-04-19 Shizuoka Prefecture スルファチドを標的とした抗ウイルス剤
US8076315B2 (en) 2005-10-14 2011-12-13 The Board Of Trustees Of The University Of Illinois Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists
MX373998B (es) * 2006-03-24 2020-07-22 Childrens Medical Center Uso de un modulador de células madre hematopoyeticas (hsc) para promover el crecimiento de hsc.
WO2007148332A1 (en) 2006-06-22 2007-12-27 Yeda Resaerch And Development Co. Ltd Catecholamine receptor modulation
RU2480213C2 (ru) 2006-10-20 2013-04-27 Чилдрен'З Медикал Сентер Корпорейшн Способ стимуляции регенерации тканей
WO2008073748A1 (en) * 2006-12-08 2008-06-19 University Of Rochester Expansion of hematopoietic stem cells
JP5320546B2 (ja) 2006-12-13 2013-10-23 国立大学法人名古屋大学 Ｔｏｌ１因子のトランスポザーゼ及びそれを用いたＤＮＡ導入システム
CA2742876C (en) 2008-11-06 2018-08-21 Indiana University Research & Technology Corporation Materials and methods to enhance hematopoietic stem cells engraftment procedures
JP5836262B2 (ja) 2009-03-19 2015-12-24 フェイト セラピューティクス， インコーポレイテッド サイクリックａｍｐエンハンサーおよび／またはｅｐリガンドを含む組成物、ならびにこれを調製および使用する方法
DK2760994T4 (da) 2011-09-30 2021-10-11 Bluebird Bio Inc Forbindelser til forøget viral transduktion

Also Published As

Publication number Publication date
AU2009313290B2 (en) 2016-04-21
CA2742876C (en) 2018-08-21
US9675641B2 (en) 2017-06-13
CA3203374A1 (en) 2010-05-14
JP2016007216A (ja) 2016-01-18
JP2018048156A (ja) 2018-03-29
CA3012803C (en) 2023-08-08
EP2362733B1 (en) 2017-04-12
AU2018241208B2 (en) 2020-05-21
CN108379292A (zh) 2018-08-10
CN107630001A (zh) 2018-01-26
US9107909B2 (en) 2015-08-18
CN102245758A (zh) 2011-11-16
US20140377214A1 (en) 2014-12-25
JP6632822B2 (ja) 2020-01-22
US20220313735A1 (en) 2022-10-06
AU2020220191A1 (en) 2020-09-10
AU2016206316B2 (en) 2018-07-12
US20120003189A1 (en) 2012-01-05
JP2020063263A (ja) 2020-04-23
WO2010054271A8 (en) 2010-07-01
US11241454B2 (en) 2022-02-08
JP2012508185A (ja) 2012-04-05
CA3012803A1 (en) 2010-05-14
US20160030478A1 (en) 2016-02-04
AU2009313290A1 (en) 2010-05-14
JP2023052244A (ja) 2023-04-11
AU2018241208A1 (en) 2018-11-01
EP3031907B1 (en) 2021-01-06
EP3824884A1 (en) 2021-05-26
WO2010054271A1 (en) 2010-05-14
CA2742876A1 (en) 2010-05-14
EP3031907A1 (en) 2016-06-15
AU2020220191B2 (en) 2023-06-01
EP2362733A1 (en) 2011-09-07
AU2016206316C1 (en) 2019-01-17
ZA201804932B (en) 2019-07-31
US10213460B2 (en) 2019-02-26
CN107523587A (zh) 2017-12-29
JP5846915B2 (ja) 2016-01-20
EP2362733A4 (en) 2013-05-08
US20170304362A1 (en) 2017-10-26
AU2016206316A1 (en) 2016-08-11
ES2845641T3 (es) 2021-07-27

Similar Documents

Publication Publication Date Title
ZA201804932B (en) Materials and methods to enhance hematopoietic stem cells engraftment procedures
IL267138A (en) Improved composition of cells and methods for its preparation
IL261851B (en) Reprogramming of t cells and hematopoietic cells
IL214798A0 (en) Methods and compositions for stem cell cultures
GB2458863B (en) Improved culture of stem cells
SG10201500674YA (en) Pluripotent stem cells
IL193345A0 (en) Methods and compositions for enhancing engraftment of hematopoietic stem cells
ZA201100758B (en) Differentiation of pluripotent stem cells
IL216902B (en) Methods for culturing stem and progentitor cells
PL2495302T3 (pl) Urządzenie biologiczne do ekstrakcji krwiotwórczych komórek macierzystych i mezenchymalnych komórek macierzystych z krwi obwodowej
FI20096288A0 (fi) Formulations and methods for culturing stem cells
IL228818A0 (en) Stem cell cultures
PL3323883T3 (pl) Zdefiniowane powierzchnie do hodowli komórkowej i sposoby użycia
ZA201202685B (en) Methods of preparing mesenchymal stem cells,compositions and kit thereof
ZA200810412B (en) Placental niche and use thereof to culture stem cells
GB0814249D0 (en) Uses of mesenchymal stem cells
ZA201203805B (en) Use of layer superstructures in wind power plants
ZA200905378B (en) Methods for increasing and mobilizing hematopoietic stem cells
GB2483379B (en) Solid cosmetic composition with structurant and electrolyte solution
GB2460552B (en) Stem cell culture media and methods
EP2513297A4 (en) MATERIALS AND METHODS FOR THE PRODUCTION OF PLURIPOTENT STEM CELLS
WO2010096264A9 (en) Methods for enhancing hematopoietic stem/progenitor cell engraftment
EP2294182A4 (en) CULTS OF MULTIPOTENT STEM CELLS
GB201002469D0 (en) Parthenote-derived stem cells and methods of making and using them
HK1176639A (en) Materials and methods for generating pluripotent stem cells